Mary Szela, Chief Executive Officer
Prior to being appointed as Chief Executive Officer of Novelion, Mary Szela was chief executive officer of Aegerion Pharmaceuticals since January 2016. Previously, Ms. Szela was chief executive officer of Melinta Therapeutics until August 2015, where she led the company’s revitalization effort, accelerated the lead asset into three phase programs and oversaw key business development transactions to monetize non-core assets. Before joining Melinta, she held various management positions at Abbott Laboratories, most recently as senior vice president for global strategic marketing and services. From 2008 to 2010, Ms. Szela served as president of the $8 billion U.S. pharmaceuticals division, during which time she directed the development and launch of more than eight new pharmaceutical products and multi-billion dollar sales growth for Abbott’s flagship product, Humira®. Between 2002 and 2008, Ms. Szela managed several of Abbott’s billion-dollar U.S. pharmaceutical businesses, and was VP of U.S. commercial operations. Prior to 2001, Ms. Szela held a series of leadership positions in the Abbott Hospital Products Division. She currently serves as a member of the boards of Coherus Biosciences and Suneva Medical. Ms. Szela earned an M.B.A. and a B.S. in nursing from the University of Illinois.
Gregory Perry, Chief Financial & Administration Officer
Prior to Novelion, Gregory Perry was appointed Chief Financial Officer of Aegerion Pharmaceuticals in July of 2015. Prior to that, Mr. Perry served as Chief Financial Officer of Eleven Biotherapeutics. Before joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics. Prior to joining InVivo, he served as the Executive Vice president and Chief Financial Officer of ImmunoGen. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer, Honeywell and General Electric. Mr. Perry serves on the board of directors of Ocata Therapeutics.
Ben Harshbarger, General Counsel
Ben Harshbarger previously served as General Counsel for Aegerion Pharmaceuticals since September 2016. Prior to that, he served as Aegerion's Acting General Counsel, VP, EMEA Legal Counsel and as our VP, Deputy General Counsel. Before joining Aegerion, Mr. Harshbarger served as Senior Director, Corporate Counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012, and Senior Director, Deputy General Counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger holds a J.D. from Boston College Law School and a B.A. from the University of Richmond.
Roger Louis, Global Chief Compliance Officer
Roger Louis served as Aegerion Pharmceuticals' Senior Vice President, Global Chief Compliance Officer since November 2015. Mr. Louis has extensive experience in compliance and risk management, having served most recently as Senior Vice President, Compliance & Risk Management, Chief Compliance Officer at Cubist Pharmaceuticals prior to its acquisition by Merck. Mr. Louis joined Cubist from Biogen Idec where he was Senior Vice President, Chief Compliance Officer. From 1997 to 2012, he held positions of increasing responsibility at Genzyme Corporation, including Senior Vice President, Chief Compliance Officer. Mr. Louis began his legal career as an Associate at Hale & Dorr in Boston where he practiced corporate and securities law. Mr. Louis received his J.D. from University of Chicago School of Law and his B.A. from Tufts University.
Remi Menes, Chief Commercial Officer
Remi Menes was previously Chief Commercial Officer of Aegerion Pharmaceuticals. Prior to Aegerion, Mr. Menes most recently served as the General Manager of AbbVie Finland, where he was responsible for the Affiliate's operations and P&L and its flagship product Humira. He also served as Board Member of Pharma Industry Finland. Before joining AbbVie Finland in 2013, Mr. Menes served as Area Commercial Director, Virology & Neonatal Care, Western Europe & Canada at AbbVie Europe. From 2008-2010, he was the Commercial Director, Specialty Products Division and a Member of the Affiliate Leadership Team at Abbott Canada. Between 1990 and 2008, Mr. Menes held a series of roles of increasing responsibility at Merck Frosst Canada Ltd., including Director, Sales & Marketing, in which he led the Canadian launch of SINGULAIR® for Allergic Rhinitis, and Product Manager for SINGULAIR and PROPECIA®/PROSCAR®. He holds an Executive M.B.A. and a B.Sc. in Organic Chemistry with a minor in Business Studies from Concordia University.
Linda Buono, Senior Vice President, Human Resources
Prior to Novelion, Linda Buono was Aegerion's Senior Vice President of Human Resources. Prior to Aegerion, Linda spent more than 25 years at Immunogen where she held a variety of leadership positions in Human Resources. Linda is effective in managing all the critical tasks and responsibilities of the company’s HR function and has facilitated recruitment of top talent across the organization. Importantly, she possesses the critical soft skills needed to significantly improve the success of the company. Her core attributes include courage, judgment, influence, political agility and effective communication, all of which are having an impact on the improved culture of the organization.
Jason M. Aryeh, Chairman
Novelion's Chairman, Jason Aryeh, is the Founder and managing General Partner of JALAA Equities, LP, a private hedge fund focused on the Life Sciences sector, and has served in such capacity since 1997. Mr. Aryeh serves on the Board of Directors, as Chairman of the Nominating and Governance Committee and as a member of the Compensation Committee of Ligand Pharmaceuticals. Mr. Aryeh also serves on the Board of Directors of the Cystic Fibrosis Foundation's Therapeutics Board. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.
Mark Corrigan, M.D.
Mark Corrigan was previously president and chief executive officer of Zalicus Inc. Prior to that, he was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as group vice president of global clinical research and experimental medicine. Dr. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ: CRME) and on the supervisory board of Nabriva Therapeutics AG (NASDAQ: NBRV). He previously served as a director of CoLucid Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS and served on the audit committee and nominating and governance committee and chaired the scientific affairs committee of Cubist’s board. Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
Mark DiPaolo is a partner and the General Counsel of Sarissa Capital Management LP, a registered investment advisor, since 2013. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. From 2005 to 2013, Mr. DiPaolo served as a senior member of Icahn Capital’s management team, working on investing aspects of Carl Icahn’s activist strategy. Prior to working with Icahn Capital, Mr. DiPaolo was an attorney with Willkie Farr & Gallagher LLP. Mr. DiPaolo received his B.A. degree from Fordham University and his J.D. degree from Georgetown University Law Center.
Mr. Kotler has over 23 years of experience as an investor and analyst following the healthcare industry. He is the founder and Managing Partner of Broadfin Capital, LLC which is the investment advisor for Broadfin Healthcare Master Fund, Ltd., a healthcare focused investment fund which he launched in 2005. Mr. Kotler earned a B.S. in economics from the Wharton School at the University of Pennsylvania in 1993.
John Orloff, M.D.
John Orloff, M.D., is Executive Vice President, Head of Research & Development of Alexion. Dr. Orloff has 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. Prior to joining Alexion, Dr. Orloff served as Executive Vice President, Head of Research & Development at Novelion. He previously served with Baxalta as Global Head of R&D and Chief Scientific Officer, where he advanced the company's pipeline and oversaw regulatory approval of 10 unique products and two devices. He also held executive R&D roles with Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with the Yale School of Medicine for seven years. Dr. Orloff received a Bachelor of Arts from Dartmouth College, and a M.D. from the University of Vermont College of Medicine. He completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.
Stephen L. Sabba, M.D.
Prior to being appointed to Novelion's Board of Directors, Stephen L. Sabba, M.D. was a Director of QLT since 2012, Chairman of the Audit and Risk Committee and a member of the Scientific Review and Compensation Committees. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP (since 2006), an investment fund, and a Director of Ligand (since 2008), a public biotechnology company. Previously, he was a Partner and Director of Research with Kilkenny Capital Management (2001 to 2006), a Chicago-based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors at Cornell University.
Donald K. Stern
Prior to being appointed to Novelion's Board of Directors, Donald Stern was a member of Aegerion Pharmaceuticals' Board of Directors since September 2015. Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He is also Of Counsel to Yurko, Salvesen, & Remz, PC, a boutique litigation law firm in Boston. Mr. Stern was United States Attorney for the District of Massachusetts from 1993 to 2001. He was also the chair of the U.S. Attorney General's Advisory Committee from 1996 to 1998. Mr. Stern served as the chief legal counsel to Governor Michael S. Dukakis from 1987 to 1990. He also spent seven years (1975-1982) as an assistant attorney general in the Massachusetts Attorney General's office, where he held several positions, including Chief of the Government Bureau. Previously, Mr. Stern was a partner at three major law firms, Cooley LLP, Bingham McCutchen LLP, and Hale and Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP), where his law practice focused on internal investigations, white collar defense and business litigation. He has extensive experience representing companies and individuals in complex civil, criminal and regulatory matters, with clients across a spectrum of industries, including health care, pharmaceutical, and financial services. Mr. Stern was an Advisor to President Barack Obama's Justice Department Transition Team. He currently co-chairs the American Bar Association/DOJ White Collar Liaison Committee, and is a former President of the National Association of Former U.S. Attorneys. He was a liaison to the American Bar Association Task Force on Corporate Monitors. Mr. Stern has been on the faculty of Boston College Law School and Harvard Law School. He received his LL.M. from the University of Pennsylvania, his J.D. from Georgetown University Law Center, and his B.A. from Hobart College. He also received an honorary LL.D. from the New England School of Law. Mr. Stern is a member of the Board of Directors of Blue Cross and Blue Shield of Massachusetts.
John C. Thomas, Jr.
Prior to being appointed to the Novelion Board of Directors, John Thomas, Jr. was a Director of QLT since 2012. Mr. Thomas has more than 38 years of experience in a variety of financial and accounting positions, with the last 28 years spent in the medical, pharmaceutical and device fields. Currently, Mr. Thomas also serves as Chief Financial Officer, Secretary and Director of CorMatrix (since 2001), a privately-held medical device company, and as Chief Financial Officer, Secretary and Director of Motion Reality, Inc. (since 1991), a motion capture and simulation company. Since September 2013, Mr. Thomas has served on the Board of Medovex, Inc., a publicly-traded medical device company (MDVXU). Since 2014, Mr. Thomas has served on the Board of Directors of NantKwest, Inc. a publicly-traded biotechnology company (NK). In the past ten years, Mr. Thomas served as acting Chief Financial Officer for DemeRx, Inc. (2010 to 2011); as Chief Financial Officer for MRI Interventions, Inc. (1998 to 2010), MiMedx Group, Inc. (2007 to 2008) and DARA BioSciences (2003 to 2009); and as a director of MRI Interventions, Inc. (2004 to 2011) and DARA BioSciences (2012). Previously, Mr. Thomas also served as a Trustee and subsequently the Chairman of the Finance Committee of The Walker School, a private Pre-K through 12 grade school (1999 to 2012). Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce with a Bachelor of Science in Commerce degree in 1975.
Mary Szela, Chief Executive Officer
Prior to being appointed as Chief Executive Officer of Novelion, Mary Szela was chief executive officer of Aegerion Pharmaceuticals since January 2016. Previously, Ms. Szela was chief executive officer of Melinta Therapeutics until August 2015, where she led the company’s revitalization effort, accelerated the lead asset into three phase programs and oversaw key business development transactions to monetize non-core assets. Before joining Melinta, she held various management positions at Abbott Laboratories, most recently as senior vice president for global strategic marketing and services. From 2008 to 2010, Ms. Szela served as president of the $8 billion U.S. pharmaceuticals division, during which time she directed the development and launch of more than eight new pharmaceutical products and multi-billion dollar sales growth for Abbott’s flagship product, Humira®. Between 2002 and 2008, Ms. Szela managed several of Abbott’s billion-dollar U.S. pharmaceutical businesses, and was VP of U.S. commercial operations. Prior to 2001, Ms. Szela held a series of leadership positions in the Abbott Hospital Products Division. She currently serves as a member of the boards of Novo Nordisk, Coherus Biosciences, and Suneva Medical. Ms. Szela earned an M.B.A. and a B.S. in nursing from the University of Illinois.